Recovery of trabecular and cortical bone turnover after discontinuation of risedronate and alendronate therapy in ovariectomized rats

Journal of Bone and Mineral Research

Volumn 23, Issue 10, 2008, Pages 1689-1697

  Fuchs, Robyn K ^a,b,d   Phipps, Roger J ^c   Burr, David B ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY   (United States)

^c PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^d Indiana University School of Medicine ^*  (United States)

Author keywords

Alendronate; Bisphosphonates; Ovariectomy; Risedronate; Treatment withdrawal

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; RISEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE TURNOVER; CONTROLLED STUDY; CORTICAL BONE; DRUG EFFECT; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTROGEN DEFICIENCY; FEMALE; LOW DRUG DOSE; NONHUMAN; OSTEOPOROSIS; OVARIECTOMY; RAT; SPRAGUE DAWLEY RAT; TIBIA; TISSUE SECTION;

ALENDRONATE; ANIMALS; BODY WEIGHT; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; ETIDRONIC ACID; FEMALE; OVARIECTOMY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 52949127298     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.080501     Document Type: Article

References (55)

1. Close P, Neuprez A, Reginster JY 2006 Developments in the pharmacotherapeutic management of osteoporosis. Expert Opin Pharmacother 7:1603-1615.
2. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA 1991 Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88:2095-2105.
3. Breuil V, Cosman F, Stein L, Horbert W, Nieves J, Shen V, Lindsay R, Dempster DW 1998 Human osteoclast formation and activity in vitro: Effects of alendronate. J Bone Miner Res 13:1721-1729.
4. Rodan GA, Fleisch HA 1996 Bisphosphonates: Mechanisms of action. J Clin Invest 97:2692-2696.
5. Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S, Kagan R, Chen E, Petruschke RA, Thompson DE, de Papp AE 2005 Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: A randomized double-blind study. J Bone Miner Res 20:141-151.
6. Watts NB, Josse RG, Hamdy RC, Hughes RA, Manhart MD, Barton I, Calligeros D, Felsenberg D 2003 Risedronate prevents new vertebral fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 88:542-549.
7. Pols HA, Felsenberg D, Hanley DA, Stepan J, Munoz-Torres M, Wilkin TJ, Qin-sheng G, Galich AM, Vandormael K, Yates AJ, Stych B 1999 Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 9:461-468.
8. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA 2004 Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189-1199.
9. Hosking D, Adami S, Felsenberg D, Andia JC, Valimaki M, Benhamou L, Reginster JY, Yacik C, Rybak-Feglin A, Petruschke RA, Zaru L, Santora AC 2003 Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: A randomised, placebo-controlled study. Curr Med Res Opin 19:383-394.
10. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH III, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344- 1352.
11. Cranney A, Tugwell P, Adachi J, Weaver B, Zytaruk N, Papaioannou A, Robinson V, Shea B, Wells G, Guyatt G 2002 Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 23:517-523.
12. Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V, Black D, Adachi J, Shea B, Tugwell P, Guyatt G 2002 Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 23:508-516.
13. Marcus R, Wong M, Heath H III, Stock JL 2002 Antiresorptive treatment of postmenopausal osteoporosis: Comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocr Rev 23:16-37.
14. Bagger YZ, Tanko LB, Alexandersen P, Ravn P, Christiansen C 2003 Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal. Bone 33:301-307.
15. Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, Feldstein A, Haskell WL, Hochberg MC, Torner JC, Lombardi A, Black DM 2004 Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: Results from the Fracture Intervention Trial long-term extension. J Bone Miner Res 19:1259-1269.
16. Wasnich RD, Bagger YZ, Hosking DJ, McClung MR, Wu M, Mantz AM, Yates JJ, Ross PD, Alexandersen P, Ravn P, Christiansen C, Santora AC II 2004 Changes in bone density and turnover after alendronate or estrogen withdrawal. Menopause 11:622-630.
17. Tonino RP, Meunier PJ, Emkey R, Rodriguez-Portales JA, Menkes CJ, Wasnich RD, Bone HG, Santora AC, Wu M, Desai R, Ross PD 2000 Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 85:3109-3115.
18. Mortensen L, Charles P, Bekker PJ, Digennaro J, Johnston CC Jr 1998 Risedronate increases bone mass in an early postmenopausal population: Two years of treatment plus one year of follow-up. J Clin Endocrinol Metab 83:396-402.
19. Stock JL, Bell NH, Chesnut CH III, Ensrud KE, Genant HK, Harris ST, McClung MR, Singer FR, Yood RA, Pryor-Tillotson S, Wei L, Santora AC II 1997 Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. Am J Med 103:291-297.
20. Ravn P, Bidstrup M, Wasnich RD, Davis JW, McClung MR, Balske A, Coupland C, Sahota O, Kaur A, Daley M, Cizza G 1999 Alendronate and estrogen-progestin in the long-term prevention of bone loss: Four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial. Ann Intern Med 131:935-942.
21. Greenspan SL, Emkey RD, Bone HG, Weiss SR, Bell NH, Downs RW, McKeever C, Miller SS, Davidson M, Bolognese MA, Mulloy AL, Heyden N, Wu M, Kaur A, Lombardi A 2002 Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 137:875-883.
22. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR 2006 Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial Long-term Extension (FLEX): A randomized trial. JAMA 296:2927-2938.
23. Arlot M, Meunier PJ, Boivin G, Haddock L, Tamayo J, Correa-Rotter R, Jasqui S, Donley DW, Dalsky GP, Martin JS, Eriksen EF 2005 Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res 20:1244-1253.
24. Cao Y, Mori S, Mashiba T, Westmore MS, Ma L, Sato M, Akiyama T, Shi L, Komatsubara S, Miyamoto K, Norimatsu H 2002 Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats. J Bone Miner Res 17:2237-2246.
25. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY 2005 Severely suppressed bone turnover: A potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294-1301.
26. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ 2003 The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207-1215.
27. Bilezikian JP, Rubin MR, Finkelstein JS 2005 Parathyroid hormone as an anabolic therapy for women and men. J Endocrinol Invest 28(8 Suppl):41-49.
28. Delmas P, Watts NB, Miller P, Cahall D, Bilezikian J, Lindsay R 2007 Bone turnover markers demonstrate greater earlier responsiveness to teriparatide following treatment with risedronate compared with alendronate. J Bone Miner Res S27:1092.
29. Papapoulos SE 2006 Bisphosphonate actions: Physical chemistry revisited. Bone 38:613-616.
30. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ 2001 Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296:235-242.
31. Lin JH, Russell G, Gertz B 1999 Pharmacokinetics of alendronate: An overview. Int J Clin Pract Suppl 101:18-26.
32. Lin JH 1996 Bisphosphonates: A review of their pharmacokinetic properties. Bone 18:75-85.
33. Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH 2006 Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite. Bone 38:617-627.
34. van Beek ER, Lowik CW, Ebetino FH, Papapoulos SE 1998 Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: Structure-activity relationships. Bone 23:437-442.
35. Leu CT, Luegmayr E, Freedman LP, Rodan GA, Reszka AA 2006 Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy. Bone 38:628-636.
36. Cremers SC, Pillai G, Papapoulos SE 2005 Pharmacokinetics/ pharmacodynamics of bisphosphonates: Use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet 44:551-570.
37. McClung M, Clemmesen B, Daifotis A, Gilchrist NL, Eisman J, Weinstein RS, Fuleihan Ge-H, Reda C, Yates AJ, Ravn P 1998 Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. Ann Intern Med 128:253-261.
38. Wronski TJ, Dann LM, Qi H, Yen CF 1993 Skeletal effects of withdrawal of estrogen and diphosphonate treatment in ovariectomized rats. Calcif Tissue Int 53:210-216.
39. Li QN, Liang NC, Huang LF, Wu T, Hu B, Mo LE 1998 Skeletal effects of constant and terminated use of sodium risedronate in ovariectomized rats. Zhongguo Yao Li Xue Bao 19:160-163.
40. Jee WS, Lin BY, Ma YF, Ke HZ 1995 Extra cancellous bone induced by combined prostaglandin E2 and risedronate administration is maintained after their withdrawal in older female rats. J Bone Miner Res 10:963-970.
41. Thompson DD, Simmons HA, Pirie CM, Ke HZ 1995 FDA Guidelines and animal models for osteoporosis. Bone 17(4 Suppl):125S-133S.
42. Martin EA, Ritman EL, Turner RT 2003 Time course of epiphyseal growth plate fusion in rat tibiae. Bone 32:261-267.
43. Hansson LI, Menander-Sellman K, Stenstrom A, Thorngren KG 1972 Rate of normal longitudinal bone growth in the rat. Calcif Tissue Res 10:238-251.
44. Lin BY, Jee WS, Ma YF, Ke HZ, Kimmel DB, Li XJ 1994 Effects of prostaglandin E2 and risedronate administration on cancellous bone in older female rats. Bone 15:489-496.
45. Li QN, Liang NC, Huang LF, Wu T, Hu B, Mo LE 1999 Skeletal effects of constant and terminated use of risedronate on cortical bone in ovariectomized rats. J Bone Miner Metab 17:18-22.
46. Ogawa K, Hori M, Takao R, Sakurada T 2005 Effects of combined calcitonin and alendronate treatment on the architecture and strength of bone in ovariectomized rats. J Bone Miner Metab 23:351-358.
47. Uludag H 2002 Bisphosphonates as a foundation of drug delivery to bone. Curr Pharm Des 8:1929-1944.
48. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: Standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595-610.
49. Yao W, Su M, Zhang Q, Tian X, Setterberg RB, Blanton C, Lundy MW, Phipps R, Jee WS 2007 Risedronate did not block the maximal anabolic effect of PTH in aged rats. Bone 41:813-819.
50. Lin JH, Chen IW, Duggan DE 1992 Effects of dose, sex, and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats. Drug Metab Dispos 20:473-478.
51. Lin JH, Duggan DE, Chen IW, Ellsworth RL 1991 Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals. Drug Metab Dispos 19:926-932.
52. Watts NB, Chines A, Olszynski WP, McKeever CD, McClung MR, Zhou X, Grauer A 2008 Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 19:365-372.
53. Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA, Kavanagh KL, Triffitt JT, Lundy MW, Plupps RJ, Barnett BL, Coxon FP, Rogers MJ, Watts NB, Ebetino FH 2007 Bisphosphonates: An update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci 1117:209-257.
54. Khan SA, Kanis JA, Vasikaran S, Kline WF, Matuszewski BK, McCloskey EV, Beneton MN, Gertz BJ, Sciberras DG, Holland SD, Orgee J, Coombes GM, Rogers SR, Porras AG 1997 Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res 12:1700-1707.
55. Mitchell DY, Heise MA, Pallone KA, Clay ME, Nesbitt JD, Russell DA, Melson CW 1999 The effect of dosing regimen on the pharmacokinetics of risedronate. Br J Clin Pharmacol 48:536-542.